ALLEGAN, Mich. — Perrigo Co. has begun shipping betamethasone valerate foam 0.12%, a treatment for psoriasis.
The company said Tuesday that the product, released according to the date certain launch settlement previously announced, is the generic equivalent of Stiefel’s Luxiq Foam.
Cobrek Pharmaceuticals Inc., recently acquired by Perrigo, was the first to file for the generic product, making it eligible for 180 days of marketing exclusivity, according to Perrigo.
Betamethasone valerate foam 0.12% is indicated for the treatment of corticosteroid-responsive scalp psoriasis. Brand annual sales are about $40 million, based on Symphony Health data cited by Perrigo.
"We are very proud to be launching our sixth foam product, a dosage form which requires specialized development and manufacturing capabilities," commented Perrigo chairman and chief executive officer Joseph Papa.
